Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction CancerRonan J. Kelly, Markus Moehler|New England Journal of Medicine|2021Cited by 1.7k
The alveolar immune cell landscape is dysregulated in checkpoint inhibitor pneumonitisKarthik Suresh, Franco R. D’Alessio, Laura C. Cappelli et al.|Journal of Clinical Investigation|2019Cited by 198
Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22–05): a single-arm, phase 1b–2 trialDaniel V.T. Catenacci, Yung‐Jue Bang, Yoon‐Koo Kang et al.|The Lancet Oncology|2020Cited by 190